Eterna Therapeutics' (ERNA) shares nearly doubled in early trading on Tuesday after the company reported positive results from a preclinical study of its lead cell therapy product ERNA-101
Eterna said the proof-of-concept study demonstrated "massive" T cell infiltration after only one dose, with reduced tumor burden and extended survival in mice with ovarian cancer.
By changing the tumor microenvironment from having low immune activity to an active immune environment, ERNA-101 "may not only lead to improved therapeutic outcomes as a monotherapy but is also anticipated to significantly enhance the efficacy of CAR-T and CAR-NK cell therapies in the future," the company said.
Regarding safety, body weight distribution showed no significant difference between the ERNA-101 and control groups, Eterna said.
Price: 0.4959, Change: +0.19, Percent Change: +60.49
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。